Expertise in
25
conditions

Dr. Frederick Locke

Internal Medicine
Moffitt Cancer Center, Magnolia Campus
12902 Usf Magnolia Dr, 
Tampa, FL 
Offers Telehealth
21 Years of Experience
Expertise in
25
conditions
Moffitt Cancer Center, Magnolia Campus
12902 Usf Magnolia Dr, 
Tampa, FL 

Overview

Frederick Locke is an Internal Medicine provider in Tampa, Florida. Dr. Locke has been practicing medicine for over 21 years is highly rated in 25 conditions, according to our data. His top areas of expertise are B-Cell Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Transplant, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 257 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Internal Medicine

Licenses

Internal Medicine in IL

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Florida Blue
  • EPO
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Sunshine Health
  • EPO
  • HMO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 4 Less Insurance Carriers -

Locations

Moffitt Cancer Center, Magnolia Campus
12902 Usf Magnolia Dr, Tampa, FL 33612

Additional Areas of Focus

Dr. Locke has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

Phase 1/1b Trial of Donor γδ T--Cell Infusion for Treatment of Patients With Acute Myeloid Leukemia at High Risk of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation
Phase 1/1b Trial of Donor γδ T--Cell Infusion for Treatment of Patients With Acute Myeloid Leukemia at High Risk of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation
Enrollment Status: Active_not_recruiting
Publish Date: February 09, 2026
Intervention Type: Biological
Study Drug: Gamma Delta T-Cell Infusion
Study Phase: Phase 1
A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression
A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression
Enrollment Status: Completed
Publish Date: February 06, 2026
Intervention Type: Drug, Procedure
Study Drugs: Pacritinib, Sirolimus, Tacrolimus
Study Phase: Phase 1/Phase 2
CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease
CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease
Enrollment Status: Completed
Publish Date: January 07, 2026
Intervention Type: Drug
Study Drugs: BMS-986004, Sirolimus, Tacrolimus
Study Phase: Phase 1
Reduced-Intensity Fludarabine, Melphalan, and Total Body Irradiation Conditioning for Transplantation of HLA-Haploidentical Related Hematopoietic Cells (Haplo-HCT) For Patients With Hematologic Malignancies
Reduced-Intensity Fludarabine, Melphalan, and Total Body Irradiation Conditioning for Transplantation of HLA-Haploidentical Related Hematopoietic Cells (Haplo-HCT) For Patients With Hematologic Malignancies
Enrollment Status: Completed
Publish Date: December 11, 2025
Intervention Type: Radiation, Drug
Study Drugs: Fludarabine, Melphalan
Study Phase: Phase 2
A Pilot Study of Atezolizumab (MPDL3280A) Following Adoptive Cell Transfer in Active Hematologic or Solid Tumor Malignancies
A Pilot Study of Atezolizumab (MPDL3280A) Following Adoptive Cell Transfer in Active Hematologic or Solid Tumor Malignancies
Enrollment Status: Active_not_recruiting
Publish Date: October 23, 2025
Intervention Type: Procedure, Other, Drug
Study Phase: Phase 1
A Prospective Randomized Study of a Personalized Approach to the Inpatient Management of Hospitalized Oncology Patients With Hyperglycemia
A Prospective Randomized Study of a Personalized Approach to the Inpatient Management of Hospitalized Oncology Patients With Hyperglycemia
Enrollment Status: Completed
Publish Date: January 20, 2023
Intervention Type: Drug
Study Phase: Early Phase 1
Evaluating the Safety and Biological Activity of a Dendritic Cell Survivin Vaccine in Patients With Multiple Myeloma Undergoing Autologous Hematopoietic Cell Transplantation
Evaluating the Safety and Biological Activity of a Dendritic Cell Survivin Vaccine in Patients With Multiple Myeloma Undergoing Autologous Hematopoietic Cell Transplantation
Enrollment Status: Completed
Publish Date: November 14, 2022
Intervention Type: Biological, Drug, Procedure
Study Drugs: Survivin Vaccine, Prevnar 13, Granulocyte-colony Stimulating Factor
Study Phase: Early Phase 1
Evaluation of Panobinostat (LBH589) as Maintenance Therapy in Multiple Myeloma Following Autologous Hematopoietic Cell Transplantation
Evaluation of Panobinostat (LBH589) as Maintenance Therapy in Multiple Myeloma Following Autologous Hematopoietic Cell Transplantation
Enrollment Status: Completed
Publish Date: November 01, 2022
Intervention Type: Drug
Study Drug: Panobinostat
Study Phase: Phase 2
Ofatumumab in Combination With Glucocorticoids for Primary Therapy of Chronic Graft Versus Host Disease
Ofatumumab in Combination With Glucocorticoids for Primary Therapy of Chronic Graft Versus Host Disease
Enrollment Status: Completed
Publish Date: October 06, 2022
Intervention Type: Drug
Study Drug: Ofatumumab
Study Phase: Phase 1/Phase 2
A Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haploidentical Peripheral Blood Stem Cell Transplantation
A Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haploidentical Peripheral Blood Stem Cell Transplantation
Enrollment Status: Completed
Publish Date: September 16, 2021
Intervention Type: Drug, Procedure, Radiation
Study Phase: Phase 1
A Phase II Trial Evaluating the Use of a Histone Deacetylase Inhibitor Panobinostat for Graft Versus Host Disease (GVHD) Prevention
A Phase II Trial Evaluating the Use of a Histone Deacetylase Inhibitor Panobinostat for Graft Versus Host Disease (GVHD) Prevention
Enrollment Status: Completed
Publish Date: July 21, 2021
Intervention Type: Drug
Study Drugs: Panobinostat, Sirolimus, Tacrolimus
Study Phase: Phase 2
A Phase I/IB Study of Ipilimumab or Nivolumab in Patients With Relapsed Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation
A Phase I/IB Study of Ipilimumab or Nivolumab in Patients With Relapsed Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation
Enrollment Status: Completed
Publish Date: June 24, 2021
Intervention Type: Biological, Other
Study Phase: Phase 1
View 11 Less Clinical Trials

257 Total Publications

Plasma cell identity escape drives resistance to anti-BCMA T-cell-redirecting therapy in multiple myeloma.
Plasma cell identity escape drives resistance to anti-BCMA T-cell-redirecting therapy in multiple myeloma.
Journal: bioRxiv : the preprint server for biology
Published: December 19, 2025
Similar Doctors
Expertise in
41
conditions
Dr. Taiga Nishihori
Internal Medicine
Expertise in
41
conditions
Dr. Taiga Nishihori
Internal Medicine

Moffitt Cancer Center, Magnolia Campus

12902 Usf Magnolia Dr, 
Tampa, FL 
 (0.1 miles away)
813-723-4775
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Taiga Nishihori is an Internal Medicine provider in Tampa, Florida. Dr. Nishihori is highly rated in 41 conditions, according to our data. His top areas of expertise are Multiple Myeloma, Graft Versus Host Disease (GvHD), Chronic Graft Versus Host Disease (cGvHD), Bone Marrow Transplant, and Bone Graft. Dr. Nishihori is currently accepting new patients.

Expertise in
22
conditions
Dr. Melissa Alsina
Internal Medicine
Expertise in
22
conditions
Dr. Melissa Alsina
Internal Medicine

Moffitt Magnolia Campus

12902 Usf Magnolia Dr, 
Tampa, FL 
 (0.1 miles away)
888-663-3488
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Melissa Alsina is an Internal Medicine provider in Tampa, Florida. Dr. Alsina is highly rated in 22 conditions, according to our data. His top areas of expertise are Multiple Myeloma, Smoldering Multiple Myeloma, Plasmacytoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
31
conditions
Dr. Aleksandr Lazaryan
Internal Medicine
Expertise in
31
conditions
Dr. Aleksandr Lazaryan
Internal Medicine

Moffitt Cancer Center, Magnolia Campus

12902 Usf Magnolia Dr, 
Tampa, FL 
 (0.1 miles away)
813-856-9147
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Aleksandr Lazaryan is an Internal Medicine provider in Tampa, Florida. Dr. Lazaryan is highly rated in 31 conditions, according to our data. His top areas of expertise are Graft Versus Host Disease (GvHD), Diffuse Large B-Cell Lymphoma (DLBCL), Chronic Graft Versus Host Disease (cGvHD), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Lazaryan is currently accepting new patients.

Frequently Asked Questions about Dr. Frederick Locke

How do I make an appointment with Dr. Frederick Locke?

You can book an appointment with Dr. Frederick Locke by calling their office at 813-692-4252. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Frederick Locke a top-rated expert for B-Cell Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Frederick Locke is classified as an Elite expert for B-Cell Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Frederick Locke specialize in?

While Dr. Frederick Locke is a Internal Medicine, they have specific expertise in B-Cell Lymphoma, Non-Hodgkin Lymphoma, and Diffuse Large B-Cell Lymphoma (DLBCL). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. Frederick Locke participate in research or clinical trials?

Yes. Dr. Frederick Locke has published 257 articles and abstracts on conditions like B-Cell Lymphoma. You can view a list of Dr. Frederick Locke's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Frederick Locke accept my insurance?

Dr. Frederick Locke accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 813-692-4252 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Locke's expertise for a condition
ConditionClose
View All 14 Advanced Conditions
View All 27 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile